secwatch / observer

8-K filed November 12, 2024, 6:59 PM ET ticker SYRE CIK 0001636282

other material confidence high sentiment positive materiality 0.85

Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing

Spyre Therapeutics, Inc.

SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.
No serious adverse events; all adverse events mild; no Grade 2+ TEAEs; no trial discontinuations.
Complete α4β7 receptor saturation maintained through Day 57 with single 300mg dose.
Phase 2 UC platform trial expected to start mid-2025; ~500 subjects, 12-week induction + 38-week maintenance.
Portfolio maintenance dosing guidance updated to Q3M-Q6M for monotherapies and combinations.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-24-046860
form_type: 8-K
ticker: SYRE
cik: 0001636282
company_name: Spyre Therapeutics, Inc.
filed_at: 2024-11-12T23:59:59+00:00
discovered_at: 2026-05-14T18:03:09.057878+00:00
generated_at: 2026-05-30T01:58:26.156937+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-24-046860
json_url: https://secwatch.observer/filing/0001628280-24-046860.json
markdown_url: https://secwatch.observer/filing/0001628280-24-046860.md
text_url: https://secwatch.observer/filing/0001628280-24-046860.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/0001628280-24-046860-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/syre-20241112.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Liberty Global names Stephen van Rooyen as Ziggo Group CEO; plans Amsterdam listing in 2027

Liberty Global Ltd. June 1, 2026, 4:07 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MDAI

Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026

Spectral AI, Inc. June 1, 2026, 4:01 PM ET other_material Items 5.07, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001628280-24-046860

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.